Search alternatives:
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
linear decrease » linear increase (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
linear decrease » linear increase (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
17421
Table 3_Clinical features and prognosis of NMOSD patients with positive autoimmune antibodies.docx
Published 2025“…</p>Results<p>(1) Anti-CTD Abs (+): higher proportion of female patients, increased relapse frequency; decreased red blood cell (RBC) count and aspartate aminotransferase (AST) levels. (2) ATAbs (+): greater incidence of acute brainstem syndrome (ABS); reduced peripheral leukocyte, neutrophil, and lymphocyte counts; elevated serum urea levels. (3) Double (+): marked female predominance, higher incidence of ABS, decreased RBC count, hemoglobin (Hb) levels, and cerebrospinal fluid (CSF) chloride concentration; elevated serum urea. (4) AQP4-IgG association: AQP4-IgG-positive patients were more frequently female, with higher prevalence of anti-CTD Abs positivity but lower prevalence of ATAbs positivity. (5) Prognostic analysis: both double-positive and single-antibody-positive groups showed higher disability (EDSS ≥4.0/≥6.0) compared with antibody-negative patients, although no significant differences were observed between the two single-antibody subgroups. (6) Multivariate analysis identified combined antibody positivity (OR = 16.292), baseline EDSS score (OR = 3.179), and age at onset (OR = 1.052) as independent predictors of poor clinical outcomes.…”
-
17422
Data_Sheet_1_The association between Geriatric Nutritional Risk Index and KSD disease: results from National Health and Nutrition Examination Survey 2007–2018.ZIP
Published 2024“…</p>Conclusion<p>The study underscores a significant, albeit nonlinear, association between elevated GNRI levels and decreased KSD prevalence. …”
-
17423
Data_Sheet_1_The association between Geriatric Nutritional Risk Index and KSD disease: results from National Health and Nutrition Examination Survey 2007–2018.ZIP
Published 2024“…</p>Conclusion<p>The study underscores a significant, albeit nonlinear, association between elevated GNRI levels and decreased KSD prevalence. …”
-
17424
Figure 6 from Membrane-bound Heat Shock Protein mHsp70 Is Required for Migration and Invasion of Brain Tumors
Published 2025“…<p>Inhibition of mHsp70 results in decreased motility of patient-derived brain tumor cells. …”
-
17425
Post-traumatic stress disorder in German youth: representative claims data pre- vs. intra-COVID-19-pandemic
Published 2025“…Quarterly incidence in female children with high SES showed a significant increase in slope pre-COVID to intra-COVID (<i>p</i> = .018). …”
-
17426
Table 1_Dietary fiber intake and hippocampal gray matter volume: an exploratory cross-sectional study in healthy adults.docx
Published 2025“…Introduction<p>Alzheimer’s disease and related dementia (ADRD) are associated with significance societal costs and economic burdens. Prior research has found that ADRD is associated with decreases in cortical gray matter volume (GMV) in the hippocampus.…”
-
17427
Glucose and G-6-P levels modulate HK2-<i>SOX10</i> mRNA association and <i>SOX10</i> mRNA translation.
Published 2025“…<p><b>(A)</b> Western blot analysis of HK2 and SOX10 protein level in A375 cells cultured for 24 h with decreasing concentrations of glucose or under glucose starvation, as indicated. …”
-
17428
-
17429
Functional assays of neurotoxicity testing of α-terpineol in Wistar rats
Published 2025“…This study in Wistar rats aimed to investigate the impacts of α- terpineol, a natural compound, on neurotoxicity. Forty-eight healthy Wistar rats, including 24 males and 24 females, were obtained, acclimated for 7 days, and housed in controlled environmental conditions with a balanced diet and <i>ad libitum</i> access to water. …”
-
17430
Osseointegration of an innovative functionally gradient biomimetic scaffold based on Voronoi-Tessellation for the design of orthopaedic implants
Published 2025“…<p>The geometry and pore size of porous structures have a significant impact on osseointegration in orthopaedic implant design. …”
-
17431
Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
17432
Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
17433
Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
17434
Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
17435
Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
17436
Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
17437
Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
17438
Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
17439
Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
17440
Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”